En Es
Categories

Industry News

QIAGEN Enters into Agreement to Acquire STAT-Dx

By Labmedica International staff writers
13 Feb 2018

Image: Qiagen plans to acquire diagnostics developer STAT-Dx for up to $191 million, in a deal designed to facilitate the buyer's planned launch later this year of the QIAstat-Dx platform, based on STAT-Dx’s proprietary DiagCORE technology (Photo courtesy of STAT-Dx).QIAGEN N.V. (The Netherlands) has entered into an agreement to acquire STAT-Dx (Barcelona, Spain), a privately-held company which develops next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.

The system, which will be branded as QIAstat-Dx, enables scalable Sample to Insight processing of up to 48 molecular targets simultaneously for diagnosing syndromes, such as serious respiratory or gastrointestinal infections, as well as for use in oncology. With cost-efficient, easy-to-use assays suitable for any clinical sample type, the system can provide qualitative as well as quantitative insights into the precise cause of various syndromes in about one hour.

Based on the proprietary DiagCORE technology, the system received a first CE-IVD marking in January 2018. The system utilizes cost-efficient, single-use cartridges with built-in sample processing and all reagents on board. The cartridges are loaded with QIAGEN sample and assay technologies and a lab technician only needs to load a clinical sample into a cartridge and place it in the analyzer, requiring less than one minute of hands-on time.

The flexible modular system, which has bi-directional LIS (laboratory information system) interface capabilities, is designed to operate in a range of near-patient clinical settings, eliminating the delay of sending samples to a centralized laboratory. The cartridges are processed in a scalable, proprietary and fully integrated platform, which can be configured from one to eight modules, independently running cartridges with predefined assay protocols and managed via a touchscreen that offers simple step-by-step directions.

QIAstat-Dx is planned to be further developed with the aim of becoming the first analyzer that combines capabilities to run the highest multiplexing molecular diagnostic assays with the ability to quantitate and also process immunoassays. The first two tests, which are extensive respiratory and gastrointestinal (GI) panels, are to be launched in Europe in the second half of 2018, in the US in 2019 following regulatory clearance, and in other markets worldwide. Additional tests are under development for infectious diseases, immune response monitoring, oncology and companion diagnostics.

“QIAstat-Dx represents the next generation of innovation for multiplex syndromic testing, using powerful QIAGEN technologies and a real-time PCR technology that will allow for a much broader range of applications and drive the dissemination of molecular testing. The system is designed for significantly more cost-efficient test processing as required by the current reimbursement environment. Additional application areas for this system include companion diagnostics, quantitative analysis and immunoassay tests, offering customers a new level of flexibility and accurate diagnosis designed to support better outcomes for patients and healthcare systems,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. “We look forward to adding QIAstat-Dx to our portfolio of Sample to Insight solutions. This is further confirmation as to how we are leveraging our advantages in sample and assay technologies, our leadership in providing solutions for infectious disease testing and the global reach of our commercial teams.”

“We are excited about accelerating the commercialization of our technology to bring fast, cost-effective syndromic testing closer to care for patients and healthcare providers. At the closing of the transaction, we will build on the achievements of our fantastic team in developing a best-in-class system and leverage QIAGEN’s resources with extensive R&D and commercial reach around the world,” said Jordi Carrera, co-founder and Chief Executive Officer of STAT-Dx.



E-mail Print
FaceBook Twitter Google+ Linked in

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including complete kits for pre-defined applications in sample preparation and analysis, and individual enzymes and reagents. It also offers instruments for automating the full range of laboratory procedures, from the initial sample preparation to the final test result.
More info

More articles about QIAGEN

12 Jan 2017
Qiagen Acquires Bioinformatics Firm OmicSoft
QIAGEN N.V., a provider of sample and assay technologies, has acquired OmicSoft Corporation, which focuses on biomarker data management, visualization, and analysis.
Read More

Additional news

08 Jan 2019
New AI Technology Pinpoints Negative Symptoms in Cancer Patients
Researchers from the University of Surrey and the University of California have developed a new artificial intelligence (AI) tool, which can predict symptoms and their severity throughout the course of a cancer patient's treatment.
Read More
08 Jan 2019
Luminex Acquires MilliporeSigma Flow Cytometry Portfolio
Luminex Corporation has completed its previously announced acquisition of MilliporeSigma's flow cytometry portfolio.
Read More
31 Dec 2018
Deep Learning Technique Could Reveal Transparent Features in Medical Images
Engineers at the Massachusetts Institute of Technology have developed a deep learning technique that can reveal images of transparent features or objects that are nearly impossible to decipher in almost total darkness.
Read More
31 Dec 2018
Next-Gen Products Driving Global POC Molecular Diagnostics Market
The global point of care (POC) molecular diagnostics market is expected to grow at a CAGR of close to 14% during the period 2019-2023, driven mainly by the growing number of M&As and collaborations, and rising focus on next-generation products.
Read More
31 Dec 2018
Increased Breast Cancer Driving Global Digital Breast Tomosynthesis Market
The global digital breast tomosynthesis market is expected to grow at a CAGR of around 13% for the period 2019-2023, driven by the increasing incidence of breast cancer, growing popularity of digital breast tomosynthesis and consistent launch of new products.
Read More
31 Dec 2018
Global Urinalysis Market to Reach USD 1.5 Billion by 2024
The global urinalysis market is expected to grow at a steady CAGR of 5.40% over the 2016-2024 period to reach a value of USD 1.5 billion by the end of 2024, propelled mainly by the rising incidence of diabetes and urinal infections, globally.
Read More
31 Dec 2018
Bruker Completes Acquisition of Alicona Imaging
Bruker Corporation has completed its previously announced acquisition of Alicona Imaging GmbH, a provider of optical-based metrology products.
Read More
25 Dec 2018
New AI-Based Solutions Create Possibility for Early Cancer Screening
Two new Artificial Intelligence- (AI) based products released at this year’s Radiological Society of North America (RSNA) annual meeting in Chicago, USA, could create possibility for large-scale early cancer screening globally.
Read More
25 Dec 2018
Network-Based AI Engine Performs Airway Segmentation from CT Images
A new 2.5D convolutional neural network (CNN)-based artificial intelligence (AI) engine enables accurate airway segmentation from computed tomography (CT) images without any human interaction.
Read More
Copyright © 2000-2019 TradeMed.com. All rights reserved. | Terms And Conditions